PLANNING RESEARCH AND DEVELOPMENT OF NEW DRUGS TO ASSURE REGULATORY APPROVAL

被引:0
|
作者
HURLEY, FL
机构
来源
FOOD AND DRUG LAW JOURNAL | 1984年 / 39卷 / 03期
关键词
D O I
暂无
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
引用
收藏
页码:312 / 317
页数:6
相关论文
共 50 条
  • [41] New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval
    Bertele', Vittorio
    Assisi, Alessandro
    Di Muzio, Valeria
    Renzo, Danila
    Garattini, Silvio
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (09) : 879 - 889
  • [42] REGULATORY PROCEDURES IN SECURING APPROVAL FOR NEW SWEETENERS
    SNODIN, DJ
    FOOD CHEMISTRY, 1985, 16 (3-4) : 303 - 320
  • [43] New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval
    Vittorio Bertele’
    Alessandro Assisi
    Valeria Di Muzio
    Danila Renzo
    Silvio Garattini
    European Journal of Clinical Pharmacology, 2007, 63 : 879 - 889
  • [44] Research and Development Costs of New Drugs - Reply
    Wouters, Olivier J.
    McKee, Martin
    Luyten, Jeroen
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 517 - 518
  • [45] Antifungal drugs: New insights in research & development
    Nicola, Andre Moraes
    Albuquerque, Patricia
    Paes, Hugo Costa
    Fernandes, Larissa
    Costa, Fabricio F.
    Kioshima, Erika Seki
    Rodrigues Abadio, Ana Karina
    Bocca, Anamelia Lorenzetti
    Felipe, Maria Sueli
    PHARMACOLOGY & THERAPEUTICS, 2019, 195 : 21 - 38
  • [46] NEW DRUGS - RESEARCH-DEVELOPMENT-MARKETING
    BRUGMANS, J
    JOURNAL DE PHARMACOLOGIE, 1974, 5 : 109 - 109
  • [47] Development and regulatory approval of a new systemic targeted therapy for advanced hepatocellular carcinoma.
    Pasche, Boris
    Benson, Al B.
    Kudo, Masatoshi
    Shields, Anthony F.
    Jimenez, Hugo
    Azmi, Asfar S.
    Barbault, Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 613 - 613
  • [49] PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
    Noriomi Matsumura
    Masaki Mandai
    International Journal of Clinical Oncology, 2024, 29 : 493 - 494
  • [50] PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
    Matsumura, Noriomi
    Mandai, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 493 - 494